Financial Architects (New Jersey)’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | $215K | Buy |
2,794
+38
| +1% | +$3.03K | 0.03% | 304 |
|
|
2023
Q1 | $229K | Buy |
2,756
+221
| +9% | +$18.3K | 0.04% | 294 |
|
|
2022
Q4 | $218K | Buy |
+2,535
| New | +$201K | 0.04% | 307 |
|
|
2022
Q1 | – | Sell |
-3,191
| Closed | -$232K | – | 345 |
|
|
2021
Q4 | $232K | Sell |
3,191
-50
| -2% | -$3.44K | 0.03% | 306 |
|
|
2021
Q3 | $226K | Buy |
3,241
+50
| +2% | +$3.51K | 0.03% | 301 |
|
|
2021
Q2 | $220K | Sell |
3,191
-520
| -14% | -$34.7K | 0.03% | 316 |
|
|
2021
Q1 | $240K | Sell |
3,711
-70
| -2% | -$4.51K | 0.04% | 287 |
|
|
2020
Q4 | $220K | Hold |
3,781
| – | – | 0.04% | 278 |
|
|
2020
Q3 | $239K | Sell |
3,781
-868
| -19% | -$60.2K | 0.05% | 233 |
|
|
2020
Q2 | $358K | Buy |
4,649
+163
| +4% | +$12.5K | 0.08% | 168 |
|
|
2020
Q1 | $335K | Hold |
4,486
| – | – | 0.09% | 159 |
|
|
2019
Q4 | $292K | Sell |
4,486
-134
| -3% | -$8.73K | 0.06% | 202 |
|
|
2019
Q3 | $293K | Buy |
4,620
+134
| +3% | +$8.76K | 0.07% | 194 |
|
|
2019
Q2 | $303K | Sell |
4,486
-674
| -13% | -$44.3K | 0.06% | 203 |
|
|
2019
Q1 | $336K | Buy |
5,160
+74
| +1% | +$4.92K | 0.06% | 222 |
|
|
2018
Q4 | $319K | Sell |
5,086
-1,469
| -22% | -$103K | 0.06% | 203 |
|
|
2018
Q3 | $506K | Sell |
6,555
-1,821
| -22% | -$138K | 0.08% | 177 |
|
|
2018
Q2 | $593K | Sell |
8,376
-773
| -8% | -$54.6K | 0.11% | 141 |
|
|
2018
Q1 | $690K | Sell |
9,149
-1,704
| -16% | -$135K | 0.13% | 120 |
|
|
2017
Q4 | $777K | Sell |
10,853
-836
| -7% | -$63.5K | 0.13% | 121 |
|
|
2017
Q3 | $947K | Sell |
11,689
-1,202
| -9% | -$91.9K | 0.17% | 104 |
|
|
2017
Q2 | $913K | Sell |
12,891
-718
| -5% | -$47.8K | 0.16% | 105 |
|
|
2017
Q1 | $924K | Sell |
13,609
-368
| -3% | -$25.9K | 0.16% | 105 |
|
|
2016
Q4 | $1M | Buy |
13,977
+1,044
| +8% | +$77.6K | 0.24% | 83 |
|
|
2016
Q3 | $1.02M | Buy |
12,933
+3,044
| +31% | +$247K | 0.27% | 76 |
|
|
2016
Q2 | $825K | Buy |
9,889
+2,690
| +37% | +$239K | 0.23% | 89 |
|
|
2016
Q1 | $661K | Sell |
7,199
-746
| -9% | -$67.3K | 0.24% | 88 |
|
|
2015
Q4 | $804K | Buy |
7,945
+145
| +2% | +$15.1K | 0.32% | 75 |
|
|
2015
Q3 | $766K | Buy |
7,800
+975
| +14% | +$108K | 0.32% | 69 |
|
|
2015
Q2 | $799K | Buy |
6,825
+97
| +1% | +$10.6K | 0.29% | 70 |
|
|
2015
Q1 | $660K | Sell |
6,728
-1,012
| -13% | -$103K | 0.26% | 77 |
|
|
2014
Q4 | $730K | Buy |
7,740
+2,450
| +46% | +$253K | 0.32% | 67 |
|
|
2014
Q3 | $563K | Sell |
5,290
-200
| -4% | -$19.6K | 0.28% | 78 |
|
|
2014
Q2 | $455K | Buy |
5,490
+500
| +10% | +$38.9K | 0.22% | 97 |
|
|
2014
Q1 | $354K | Hold |
4,990
| – | – | 0.21% | 106 |
|
|
2013
Q4 | $375K | Buy |
4,990
+4,070
| +442% | +$283K | 0.22% | 98 |
|
|
2013
Q3 | $58K | Hold |
920
| – | – | 0.04% | 237 |
|
|
2013
Q2 | $47K | Buy |
+920
| New | +$48K | 0.03% | 248 |
|
Other funds holding GILD
Financial Architects (New Jersey)'s GILD Position: Q2 2023 in Review
Financial Architects (New Jersey) increased its Gilead Sciences (GILD) stake by 1.4% in Q2 2023, buying an estimated $3.03K and bringing the position to 2,794 shares worth $215K. The position accounts for 0.03% of the portfolio, ranked #304.
Financial Architects (New Jersey) first reported a position in GILD in Q2 2013 and has held it in 38 quarters since. The position peaked at $1.02M in Q3 2016. 1,702 funds tracked by Wall St. Rank hold GILD as of Q2 2023.
- Financial Architects (New Jersey) held 2,794 shares of Gilead Sciences worth $215K as of Q2 2023.
- Financial Architects (New Jersey) bought 38 Gilead Sciences shares in Q2 2023, an estimated $3.03K.
- Gilead Sciences made up 0.03% of Financial Architects (New Jersey)'s portfolio in Q2 2023, its #304 holding.
- Financial Architects (New Jersey) first reported a position in Gilead Sciences in Q2 2013 and has held it in 38 quarters since.
- Financial Architects (New Jersey)'s Gilead Sciences position peaked at $1.02M in Q3 2016.
- 1,702 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2023.
Based on Financial Architects (New Jersey)'s 13F filing for Q2 2023, filed 10 Aug 2023.